Batra Chandar M, Jain Savita, Kumar Kiran P, Goyal Monika, Kachroo Varsha, Takkar Simran, Yadav Rini
Department of Endocrinology, Indraprastha Apollo Hospital, New Delhi, India.
Endocrinology Deep Hospital, Ludhiana, Punjab, India.
Indian J Endocrinol Metab. 2024 May-Jun;28(3):295-301. doi: 10.4103/ijem.ijem_378_23. Epub 2024 Jun 26.
Dr. Hirata of Japan first described insulin autoimmune syndrome (IAS) in 1970. Seven hundred ninety-five cases of this rare syndrome have been reported from Japan and China and 29 from India. IAS has the following characteristic features 1) severe spontaneous attacks of hyperinsulinemic hypoglycaemia, 2) high total immunoreactive insulin levels, 3) elevated insulin autoantibody (IAA) titres, 4) no prior exposure to exogenous insulin, and 5) no pathological abnormalities of the pancreatic islet cells.
We treated six cases of IAS with high doses of prednisolone for 4-6 weeks and then gradually reduced the doses. Diagnosis of IAS was established by documenting Whipple's triad of symptoms and signs of hypoglycaemia, blood sugar <55 mg/dl, improvement of symptoms with dextrose infusion, inappropriately increased insulin levels >3 uU/ml, C-peptide levels >0.6 ng/ml, and increased titres of anti-insulin autoantibodies. Insulinoma and non-pancreatic tumours were ruled out by CECT (contrast-enhanced computerised tomography) or MRI (magnetic resonance imaging) of the abdomen and if necessary endoscopic ultrasonography and gallium 68 Dotanoc PET (positron enhanced tomography). Autoimmune screening and serum electrophoresis were done to rule out multiple myeloma. Monitoring of the patient's blood sugars was done by the laboratory, glucometer readings, and a freestyle libre glucose monitoring system.
Remission of hypoglycaemic episodes, hyperglycaemic episodes, and marked reduction of serum insulin and insulin autoantibodies in four out of six patients with diet therapy and steroids. Two patients resistant to steroids were treated with rituximab successfully. Patient 6 developed serious complications of cytomegalovirus and after rituximab, which were treated successfully.
A careful history including recent infections, medications, and vaccinations provides vital clues in the evaluation. An increased awareness of IAS will prevent unnecessary and costly investigations and surgery. Although it is often self-remitting, steroids are contributory in severe cases. Immunosuppressives are used successfully in cases refractory to steroids. Continuous glucose monitoring system (CGMS), by freestyle libre glucose monitoring system, provided real-time blood sugar values, total time in hypoglycaemia, and total time in the range (TIR), which proved very valuable in managing IAS patients. Low CGMS values should be corroborated clinically and with laboratory or glucometer values.
日本的平田医生于1970年首次描述了胰岛素自身免疫综合征(IAS)。日本和中国已报告795例这种罕见综合征,印度报告了29例。IAS具有以下特征:1)严重的自发性高胰岛素血症性低血糖发作;2)总免疫反应性胰岛素水平高;3)胰岛素自身抗体(IAA)滴度升高;4)既往未接触过外源性胰岛素;5)胰岛细胞无病理异常。
我们用大剂量泼尼松龙治疗6例IAS患者4 - 6周,然后逐渐减量。通过记录低血糖的Whipple三联征症状和体征、血糖<55mg/dl、葡萄糖输注后症状改善、胰岛素水平不适当升高>3uU/ml、C肽水平>0.6ng/ml以及抗胰岛素自身抗体滴度升高来确诊IAS。通过腹部CT增强扫描(CECT)或磁共振成像(MRI)排除胰岛素瘤和非胰腺肿瘤,必要时进行内镜超声检查和镓68 Dotanoc正电子发射断层扫描(PET)。进行自身免疫筛查和血清电泳以排除多发性骨髓瘤。通过实验室检测、血糖仪读数和自由式血糖监测系统对患者血糖进行监测。
6例患者中有4例通过饮食疗法和类固醇治疗,低血糖发作、高血糖发作缓解,血清胰岛素和胰岛素自身抗体显著降低。2例对类固醇耐药的患者用利妥昔单抗治疗成功。患者6在使用利妥昔单抗后出现严重的巨细胞病毒并发症,但已成功治疗。
详细的病史,包括近期感染、用药和疫苗接种情况,在评估中提供重要线索。提高对IAS的认识将避免不必要且昂贵的检查和手术。虽然IAS通常可自行缓解,但在严重病例中类固醇有帮助。免疫抑制剂在对类固醇难治的病例中使用成功。自由式血糖监测系统提供的连续血糖监测系统(CGMS)可提供实时血糖值、低血糖总时间和血糖达标总时间(TIR),这在管理IAS患者方面证明非常有价值。低CGMS值应结合临床以及实验室或血糖仪值进行核实。